Health News Releases

  • Today November 13
May 23, 2014 13:20
Antidote for rapid reversal of Pradaxa® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients
For media outside of the U.S., the UK & Canada only Boehringer Ingelheim today announces the next step in the clinical development of idarucizumab*, the investigational antidote for rapid reversal
May 23, 2014 10:55
Covidien Releases Two-Year Study Results Demonstrating Sustained Effectiveness of Drug-Coated Angioplasty Balloon Technology
Covidien’s (www.covidien.com) Stellarex™ drug-coated angioplasty balloon (Stellarex DCB) continues to be shown as safe and effective for treatment of peripheral arterial disease (PAD), according to ne
May 22, 2014 20:00
Data on Angiox (Bivalirudin Injection) in Heart Attack Patients Presented at EuroPCR and Published in European Heart Journal
During the Late Breaking Clinical Trial sessions at EuroPCR yesterday and published simultaneously in the European Heart Journal, Professor Uwe Zeymer of Klinikum Ludwigshafen, Ludwigshafen, Germany a
May 22, 2014 18:08
South-South Cooperation to Improve Diabetes Care
China, Zimbabwe and Ecuador will have an exclusive opportunity to replicate and adapt a successful diabetic foot care project originally developed in Alexandria, Egypt. This pioneering partner approac
May 22, 2014 15:25
COPD: First Phase III data show lung function benefits of tiotropium + olodaterol fixed-dose combination go beyond tiotropium (Spiriva®) alone
For media outside of the US, the UK & Canada only Boehringer Ingelheim today announced the first Phase III data for the once-daily fixed-dose combination of tiotropium and olodaterol. Results from
May 20, 2014 15:35
Pulmonx Announces First Comprehensive Report of Collateral Ventilation Assessed by the Chartis Endobronchial Catheter in Late Stage Emphysema
Pulmonx (www.pulmonx.com/us-or-international), an emerging leader in interventional pulmonology, announced today that multiple clinical abstracts examining the diagnostic and therapeutic utility of it
May 20, 2014 10:55
Quintiles Executive to Present at Jefferies 2014 Global Healthcare Conference
Quintiles CFO Kevin Gordon will present at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014 in New York City at the Grand Hyatt New York. The Quintiles presentation will beg
May 19, 2014 17:50
Ferring launches Guts4life, An Interactive Online Resource for People with Inflammatory Bowel Disease
Ferring Pharmaceuticals marks World IBD Day (May 19th) with the launch of Guts4life (www.guts4life.com), a new interactive website with information, support and inspiration for people concerned with C
May 19, 2014 10:35
IPF Phase III results published in NEJM show nintedanib* slows disease progression
For non-US health media only Results from the Phase III INPULSIS™ trials, published online today in the New England Journal of Medicine, show nintedanib* significantly slowed disease progression in
May 15, 2014 20:05
Neos Therapeutics Announces Issuance of New Patent Covering Composition of Matter for Company’s Novel ADHD Products
Neos Therapeutics, Inc. (“Neos” or “the Company”), a highly differentiated oral drug delivery company with a portfolio of proprietary technologies and a late-stage pipeline of innovative controlled re
May 15, 2014 16:15
New analysis shows Boehringer Ingelheim’s Giotrif® (afatinib) is the first treatment to demonstrate significant overall survival benefit for patients with a specific type of lung cancer
For Ex-US and Ex-UK Media Only Boehringer Ingelheim today announced new overall survival results from a post-hoc analysis combining the data of two Phase III trials (LUX-Lung 3 and LUX-Lung 6). The
May 15, 2014 13:40
LFB SA Announces That First Patient Has Begun Treatment with New Coagulation Factor VIIa (Recombinant) in Global Phase 3 Clinical Trial in Hemophilia A and B with Inhibitors
LFB SA, through its U.S. subsidiary, announced today that the first patient has begun treatment with LR769 in a Phase 3 clinical trial of this novel recombinant form of human Factor VIIa in patients w
May 14, 2014 22:30
Wolters Kluwer Health, International AIDS Society Partner to Support Critical Clinical Decision Making
Wolters Kluwer Health (http://goo.gl/o2rWK), a leading global provider of information for healthcare professionals and students, announced today that it has partnered with the International AIDS Socie
May 14, 2014 20:05
Crescendo Bioscience's Vectra(R) DA Predicts Radiographic Progression in Patients With Early Rheumatoid Arthritis
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today announced the online publication of a new study in the journal Annals of the Rheumatic Diseases for Cresce
May 13, 2014 14:30
Dr. Paul A. Friedman Joins Verastem Board of Directors
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the appointment of Paul A. Friedman, M.D. to its
May 13, 2014 11:25
Quintiles Announces Agreement to Acquire Encore Health Resources
As part of its continued efforts to strengthen and expand its service capabilities across the healthcare continuum, Quintiles today announced that it has signed an agreement to acquire Encore Health R
May 08, 2014 11:50
New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients
For media outside of the U.S., the UK & Canada only Details of a new 6,000 patient study of dabigatran etexilate were announced today at the European Stroke Conference, Nice, France. The RE-SPECT E
May 07, 2014 21:45
New registry data highlight substantial global differences in stroke prevention for patients with an irregular heart beat
For media outside of the U.S., the UK & Canada only Boehringer Ingelheim today announces first worldwide data from the GLORIA™-AF Registry Programme highlighting substantial regional differences in
FightBack logo
May 07, 2014 18:05
Otsuka Wins European Marketing Authorization for Deltyba™ (delamanid)
Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European Commission has granted a marketing authorization for Deltyba™ (delamanid) for use as part of an appropriate combination regim
May 07, 2014 17:20
Quintiles Executive to Present at Bank of America Merrill Lynch 2014 Health Care Conference
Quintiles CFO Kevin Gordon will present at the Bank of America Merrill Lynch 2014 Health Care Conference on Thursday, May 15, 2014 in Las Vegas at the Encore Wynn. The Quintiles presentation will b
May 07, 2014 13:55
AHRQ Publishes Third Edition of Quintiles-Led Registries User’s Guide
Quintiles today announced that the U.S. Agency for Healthcare Research and Quality (AHRQ) has published the third edition of “Registries for Evaluating Patient Outcomes: A User’s Guide.” Quintiles’ Re
May 02, 2014 14:45
ElectroCore: Two separate studies on the treatment of migraine headache with non invasive vagus nerve stimulation are being presented at the American Association of Neurology (AAN) meeting in Philadelphia
At the AAN meeting in Philadelphia, two separate studies showed that electroCore’s non invasive vagus nerve stimulation (nVNS) therapy was effective in helping patients with different types of migrain
May 01, 2014 19:00
Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin achieved an overall survival of 6.1 months, a 1.9 month improveme
April 30, 2014 17:35
Boehringer Ingelheim to present highly anticipated Phase III data in IPF and COPD at ATS International Conference
For media outside UK, U.S. and Canada Boehringer Ingelheim announced today that the first results of the two confirmatory Phase III INPULSISTM trials, investigating nintedanib* in the treatment of
April 30, 2014 12:00
Asklepios Accelerates Investments in Equipment, Technology and Quality of Staff: Self-Imposed Claim as an Innovative Former in the Health System Makes Clear That the Safety of Patients and Employees is at the Focus
Asklepios Kliniken GmbH, holding company of the health care Group Asklepios, once again shows sustainable growth at all levels of the company. Asklepios invested in fiscal year 2013 mainly in modernis
25 per page50 per page75 per page100 per page